Blackstone exits Emcure with sale to Bain amid bleak IPO market conditions
This article was originally published in Scrip
Executive Summary
Private equity firm Blackstone is exiting the Indian company Emcure Pharmaceuticals and will divest its holding in the firm to Bain Capital for around INR6.50bn ($104.6m).